Enterococcus faecium Strains for Th17 Inflammatory Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective treatments for inflammatory and autoimmune diseases mediated by the IL-17 or Th17 pathway, with limited characterization of gut bacteria's effects on these conditions, necessitating new therapeutic approaches.
Innovation Solution
Development of compositions comprising Enterococcus faecium bacterial strains for oral administration, which reduce the severity of inflammatory responses and alleviate Th17 inflammatory reactions, effectively treating conditions such as uveitis, asthma, and rheumatoid arthritis by modulating cytokine levels and immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for inflammatory and autoimmune diseases mediated by IL-17 or Th17 pathway, then existing therapeutic options are limited, but treatment effectiveness is insufficient
Solution Approach 1:
The patent changes the therapeutic parameter from conventional treatments to specific bacterial strains (Enterococcus faecium, Lactobacillus reuteri) with demonstrated efficacy in reducing IL-17 and Th17 pathway activity. This parameter change provides both reliability through proven effectiveness and versatility through multiple bacterial strain options for treating inflammatory and autoimmune diseases
Solution Approach 2:
The patent introduces bacterial strains as intermediary agents that mediate the treatment effect by modulating the immune system and reducing IL-17/Th17 pathway activity. These bacterial intermediaries provide therapeutic benefits while allowing for multiple treatment options across different disease conditions
2Reliability
If bacterial strains are used to treat inflammatory diseases, then disease severity is reduced, but the relationship between different diseases and bacterial strains is poorly characterized
Solution Approach 1:
The patent performs preliminary characterization of bacterial strain effects on various inflammatory and autoimmune diseases before clinical application. By pre-establishing the relationships between specific bacterial strains and disease conditions through in vitro and in vivo studies, the patent reduces information loss and provides a solid evidence base for targeted therapies
Solution Approach 2:
The patent segments the broad category of inflammatory diseases into specific conditions (uveitis, asthma, rheumatoid arthritis, etc.) and matches them with specific bacterial strains based on their differential effects. This segmentation allows for precise characterization of bacterial-disease relationships while maintaining treatment reliability
Data Source
AI summary
The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.